Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2023-07-10 Director's Dealing
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
112年06月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders and directors of the company 美時化學製藥股份有限公司. It lists share counts, pledged shares, and relationships of insiders such as directors, independent directors, general manager, and other executives. The document does not contain financial statements, earnings data, or management discussion. It is a disclosure of insider shareholdings and pledges, which corresponds to reporting of personal share transactions or holdings by company directors and executives. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is 4368 characters, which is sufficient for a detailed insider shareholding report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification. Hence, the classification is DIRS with high confidence.
2023-07-10 Chinese
112年年報及股東會資料 — 2023_1795_20230615FE2.pdf
Regulatory Filings
2023-06-30 Chinese
112年年報及股東會資料 — 2023_1795_20230615F05.pdf
AGM Information Classification · 95% confidence The document is a detailed record of a company's Annual General Meeting (AGM) held in 2023 (民國一一二年 corresponds to 2023). It includes attendance details, reports presented (such as the 111年度營業報告 - 2022 business report, audit committee report, employee and director remuneration report), approval of financial statements, dividend distribution, amendments to company bylaws, issuance of restricted stock to employees, share transfer to employees, election of directors, and other shareholder meeting resolutions. The document also contains detailed election results and discussions on director competition restrictions. The presence of detailed meeting minutes, voting results, and discussions strongly indicates this is the official AGM meeting minutes document. It is not merely an announcement or a proxy statement, but the full record of the AGM proceedings. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is not a brief announcement or a regulatory filing. Confidence is high due to the comprehensive nature of the document and the presence of typical AGM content such as reports, approvals, elections, and resolutions.
2023-06-30 Chinese
112年年報及股東會資料 — 2022_1795_20230615FE4.pdf
Annual Report Classification · 100% confidence The document is titled '2022 Annual Report' and includes detailed sections typical of a full annual report such as letters to shareholders, company profile, corporate governance, capital raising, operational highlights, and comprehensive financial information including consolidated financial statements and independent auditors' reports. The length is substantial (15,000 characters) and contains actual financial data and analysis for the fiscal year ended December 31, 2022. It is not merely an announcement or a certification but the full report itself. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-06-30 Chinese
112年年報及股東會資料 — 2023_1795_20230615F17.pdf
Major Shareholding Notification Classification · 100% confidence The document contains a table listing the top ten shareholders of a company, including their shareholdings and relationships among them. It is a notification of major shareholding information, detailing ownership percentages and related parties. There is no indication of financial statements, management discussion, or other report types. The content fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding data, confirming it is not a full report or announcement of a report publication.
2023-06-30 Chinese
112年年報及股東會資料 — 2022_1795_20230615F04.pdf
Annual Report Classification · 100% confidence The document is titled as an annual report (年報) for the fiscal year 111 (which corresponds to 2022 in the Gregorian calendar) of 美時化學製藥股份有限公司 (Mesyrel Pharmaceutical Co., Ltd.). It contains detailed sections including a letter to shareholders, company overview, governance report, fundraising details, operational overview, and extensive financial data including audited consolidated and individual financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of audited financial statements and comprehensive business and financial analysis confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-06-30 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.